We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

This study is currently recruiting participants.
Verified October 2017 by 4SC AG
Sponsor:
ClinicalTrials.gov Identifier:
NCT02953301
First Posted: November 2, 2016
Last Update Posted: October 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
4SC AG
  Purpose
The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have recently achieved disease control with previous systemic therapy.

Condition Intervention Phase
Mycosis Fungoides Sezary Syndrome Lymphoma, T-Cell, Cutaneous Drug: resminostat Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study

Resource links provided by NLM:


Further study details as provided by 4SC AG:

Primary Outcome Measures:
  • PFS (Progression-free survival) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 32 months ]
    The primary objective is to determine if maintenance treatment with resminostat increases progression free survival (PFS) compared to placebo in patients with advanced stage (Stage IIB-IVB) MF or SS that have achieved disease control (complete response [CR], partial response [PR] or stable disease [SD]) with previous systemic therapy.


Secondary Outcome Measures:
  • TTSW (Time to symptom worsening): pruritus [ Time Frame: From date of randomisation to first date that criteria for symptom (pruritus) worsening have been met, up to approximately 32 months. Symptom worsening is defined as an increase of a minimum of 3 points on the visual analogue itching scale ]
    To determine if maintenance treatment with resminostat increases time to symptom (pruritus) worsening (TTSW) compared to placebo.


Other Outcome Measures:
  • TTP (Time to progression) [ Time Frame: From date of randomization until the date of first documented progression, up to approximately 32 months ]
    Compare time to progression (TTP) in patients when treated with resminostat vs placebo

  • TTNT (Time to next treatment) [ Time Frame: From date of randomisation to first date that new treatment is received, up to approximately 44 months. ]
    Compare time to next treatment (TTNT) in patients when treated with resminostat vs placebo

  • PFS2, PFS3 (Progression-free survival 2, 3) [ Time Frame: From date of start of subsequent treatment to date of progression or death due to any cause in the absence of documented PD whilst receiving second and third line therapy, respectively, up to approximately 44 months ]
    Assess the effect of maintenance treatment with resminostat by means of PFS of subsequent treatments (PFS2, PFS3)

  • ORR (Overall response rate) [ Time Frame: Percent of patients within each treatment Arm that achieve confirmed CR or PR relative to the number of patients belonging to the analysis population of interest, up to approximately 32 months. ]
    Compare overall response rate (ORR, including CR, PR) in patients when treated with resminostat vs placebo

  • DOR (Duration of response) [ Time Frame: From date confirmed CR or PR (whichever is first) until the criteria for PD have been met, up to approximately 32 months. ]
    Compare duration of response (DOR) in patients when treated with resminostat vs placebo

  • OS (Overall survival) [ Time Frame: From the day of randomisation to death from any cause, up to approximately 44 months. ]
    Compare overall survival (OS) in patients when treated with resminostat vs placebo

  • Incidence of treatment-related AEs and SAEs (Safety and tolerability) [ Time Frame: Weekly for 3 cycles, then bi-weekly during treatment phase, up to approximately 9 months ]
    Assess the safety and tolerability of resminostat

  • HrQoL (Health related quality of life) [ Time Frame: Every 28 days, up to approximately 32 months ]
    Compare changes in health related quality of life (HrQoL) parameters in patients when treated with resminostat vs placebo

  • Maximum Plasma Concentration [Cmax] [ Time Frame: At Cycle 3, Day 1 at 0.75h, 2h and 4 h after intake of trial medication / at Cycle 3, Day 5 to be done pre-dose and at 2h and 7h after intake of trial medication ]
    Assess the maximum plasma concentration [Cmax] of resminostat

  • Area Under the Curve [AUC] [ Time Frame: At Cycle 3, Day 1 at 0.75h, 2h and 4 h after intake of trial medication / at Cycle 3, Day 5 to be done pre-dose and at 2h and 7h after intake of trial medication ]
    Assess the Area Under the Curve [AUC] of resminostat


Estimated Enrollment: 150
Study Start Date: November 2016
Estimated Study Completion Date: February 2020
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: resminostat
3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
Drug: resminostat
Other Name: 4SC-201
Placebo Comparator: Placebo
3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
Drug: Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Patients with histologically confirmed MF (Stage IIB-IVB) or SS in an ongoing complete response (CR), partial response (PR) or stable disease (SD) after at least one prior systemic therapy according to local standards (including but not limited to α-interferon, bexarotene, total skin electron beam irradiation, chemotherapy) [the most recent systemic therapy must have been completed as planned or stopped due to unacceptable toxicity 2-12 weeks prior to randomisation]
  • Eastern Cooperative Oncology Group (ECOG) status score 0-2
  • Adequate haematological, hepatic and renal function

Main Exclusion Criteria:

  • Patients with progressive disease (PD)
  • Baseline corrected QT (QTc) interval > 500 milliseconds
  • Concurrent use of any other specific anti-tumour therapy including psoralen photo chemotherapy (PUVA), chemotherapy, immunotherapy, hormonal therapy, radiation therapy, or experimental medications
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02953301


Contacts
Contact: Chief Medical Officer +49 89 700763 ext 0 RESMAIN@4sc.com

  Show 51 Study Locations
Sponsors and Collaborators
4SC AG
Investigators
Principal Investigator: Rudolf Stadler, Prof. Johannes Wesling Klinikum, Minden, Germany
  More Information

Responsible Party: 4SC AG
ClinicalTrials.gov Identifier: NCT02953301     History of Changes
Other Study ID Numbers: 4SC-201-6-2015
2016-000807-99 ( EudraCT Number )
First Submitted: October 26, 2016
First Posted: November 2, 2016
Last Update Posted: October 13, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by 4SC AG:
Cutaneous T-Cell Lymphoma (CTLC)
Maintenance
resminostat
4SC
HDAC
Mycosis Fungoides
Sézary Syndrome

Additional relevant MeSH terms:
Syndrome
Mycoses
Mycosis Fungoides
Sezary Syndrome
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Disease
Pathologic Processes
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases